...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Inhibitor design by wrapping packing defects in HIV-1 proteins.
【24h】

Inhibitor design by wrapping packing defects in HIV-1 proteins.

机译:通过包装HIV-1蛋白的包装缺陷来设计抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

Two viral proteins, HIV-1 protease and HIV-1 integrase, have been targeted for inhibitor design to prevent assembly and maturation of HIV-1 virions. The enzymatic mechanism of these proteins involves side-chain groups that serve as general acids or bases. Furthermore, catalytic activity requires that water be removed from the microenvironment surrounding the chemical reaction site or be constrained to serve as an activated nucleophile. Here, we identify previously unrecognized structural features that promote water removal from polar catalytic regions. Packing defects in the form of hydrogen bonds that are insufficiently dehydrated intramolecularly, named dehydrons, anhydrous enzymatic pathway. Dehydrons become electrostatically enhanced and stabilized upon further desolvation. Thus, packing defects act synergistically with the polar active groups to enhance the enzymatic electrostatics. However, because dehydrons are sticky, they constitute targets for inhibitor design. We noticed that inhibitors attach to polar surfaces by further desolvating dehydrons, thus blocking the active sites or the sites involved in harnessing the substrate. The dehydrons are thus required for functional reasons, making them suitable targets. The differences in success when targeting HIV-1 protease, feline immunodeficiency virus protease, and HIV-1 integrase are rationalized in terms of the dehydron distribution, revealing possible improvements in the targeting strategy. Principles of design optimization are proposed to create an inhibitor that can be neutralized only at the expense of the loss of catalytic function. The possibility of using drugs that wrap dehydrons to block protein-protein associations is also discussed.
机译:HIV-1蛋白酶和HIV-1整合酶这两种病毒蛋白已被用于抑制剂设计,以防止HIV-1病毒体的组装和成熟。这些蛋白质的酶促机制涉及充当通用酸或碱的侧链基团。此外,催化活性要求从化学反应位点周围的微环境中除去水或将其约束为活化的亲核试剂。在这里,我们确定了以前无法识别的结构特征,这些特征促进了水从极性催化区域的去除。氢键形式的填充缺陷在分子内不足以脱水,称为脱水,无水酶促途径。脱水剂在进一步脱溶剂后变得静电增强并稳定。因此,堆积缺陷与极性活性基团协同作用以增强酶静电。但是,由于脱水剂是粘性的,它们构成抑制剂设计的目标。我们注意到抑制剂通过进一步使脱水剂去溶剂化而附着在极性表面上,从而阻断了活性位点或利用底物所涉及的位点。因此出于功能原因需要脱水剂,使其成为合适的靶标。靶向HIV-1蛋白酶,猫免疫缺陷病毒蛋白酶和HIV-1整合酶时成功的差异根据脱氢分布合理化,揭示了靶向策略的可能改进。提出了设计优化的原理以产生仅能以失去催化功能为代价才能中和的抑制剂。还讨论了使用包裹脱水剂的药物来阻止蛋白质-蛋白质结合的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号